Delivering Advanced Therapeutics
Critical Pharmaceuticals has an experienced, multi-skilled scientific, clinical and commercial leadership team directed by a board of international standing with a broad base of expertise.
David Gough, Chairman
David is an entrepreneur specializing in biomedical and other technology-based businesses. In the past ten years he has founded or co-founded 6 companies one of which, Vectura, has been successfully floated on AIM and moved to the main exchange in 2007. David has over 30 years of experience as a senior manager, consultant, entrepreneur and investor and has raised, or helped to raise, close to £100m in equity capital and VC funds. David has extensive board experience involving some 20 companies and has worked for or consulted to many of the world's leading pharmaceutical, healthcare and biotechnology companies.
Professor Steve Howdle PhD, Founder and Chief Scientific Officer
Steve is the co-founder of Critical Pharmaceuticals and a world-renowned scientist in the field of supercritical fluid processing with over 15 years experience in the field. Steve holds a Chair of Chemistry at The University of Nottingham and has published over 300 papers in high-level scientific journals. Over the past 10 years his research has focused on the pharmaceutical formulation of drugs using supercritical fluids and he has filed ten patents. Steve has received the Corday Morgan Medal and Award (2001) and Interdisciplinary Award (2005) of the Royal Society of Chemistry, the Jerwood Salters Environment Award (2001), Royal Society/Wolfson Research Merit Award (2003) and the DECHEMA-Award 2006 of the Max Buchner Research Foundation; only the second time this was awarded outside of Germany in the last fifty years. Steve has achieved an H-index of 40 (Web of Science).
Alan Baines, Financial Director
Alan is a chartered accountant and has over 25 years experience in working with business start-ups. Alan was senior partner in an internationally renowned business development firm and he was the author of his firms’ publication on the subject. Alan has a clear appreciation of the problems and changes faced by growing businesses and his experience in the subject has helped many companies identify, anticipate and solve such critical issues.
Dr Anjumn Shabir-Ahmed, Head Pharmaceutical Sciences
Anjumn is an expert in pharmaceutical formulation and development. She completed her PhD under the supervision of Dr. Afzal Mohammed and Professor Yvonne Perrie, researching and developing oral drug delivery particulate systems for paediatrics. She has extensive experience in GMP and GLP formulation development covering sterile and non-sterile products for small molecules, proteins and peptides. At Critical Pharmaceuticals she is responsible for leading the development team, project managing a range of internal and external collaborative projects, maintaining relationships with clients, while developing the CriticalMix platform technology.
Dr Stuart Robinson, Head of Business Development
Following the completion of a PhD at Guy’s Hospital Medical School, Stuart joined Fisons Pharmaceuticals as a Research Immunologist in 1985. With over 30 years industry experience he has worked in research, development, medical and regulatory affairs, sales, marketing, licensing and intellectual property management. Active in both the biotechnology and drug delivery areas he has held positions with Chiroscience, Andaris, Penwest, SkyePharma and latterly PepTcell. At Critical Pharmaceuticals he has responsibility for the company’s Commercial and Business Development activities.